Company news

MacroGenics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

MacroGenics Announces Date of Third Quarter 2020 Financial Results Conference Call

October 27, 2020

MacroGenics Announces Flotetuzumab Publication in Blood Advances

October 14, 2020

MacroGenics Announces MGC018 Publication in Molecular Cancer Therapeutics

September 22, 2020

MacroGenics Announces Publication of Flotetuzumab Interim Phase 1/2 Clinical Trial Results in Blood

September 21, 2020

MacroGenics Announces Development Milestone Achieved in Retifanlimab (MGA012) Collaboration with Incyte

September 20, 2020

MacroGenics Announces Presentation of MGD019 Phase 1 Data at the ESMO Virtual Congress 2020

September 19, 2020

MacroGenics Provides Update on Corporate Progress and Second Quarter 2020 Financial Results

July 29, 2020

MacroGenics Announces Date of Second Quarter 2020 Financial Results Conference Call

July 22, 2020

MacroGenics Announces Lancet Oncology Publication of Margetuximab Data in Gastric Cancer

July 8, 2020

MacroGenics Announces Presentation of Preclinical Data at the 2020 AACR Annual Meeting

June 21, 2020

MacroGenics Appoints Dr. Stephen Eck As Chief Medical Officer

June 15, 2020

MacroGenics Announces Margetuximab Granted Orphan Drug Designation in the U.S. for Gastric Cancer

June 4, 2020

MacroGenics Provides Update on FDA Review of Margetuximab for HER2-Positive Metastatic Breast Cancer

May 27, 2020

MacroGenics Announces Registration Study of Flotetuzumab in Patients with Refractory Acute Myeloid Leukemia

May 26, 2020

MacroGenics to Host Conference Call and Webcast to Review Preliminary Clinical Results for MGD013 and MGC018 to be Presented at ASCO

May 20, 2020

MacroGenics Announces Preliminary Clinical Results from MGD013 and MGC018 to be Presented at the ASCO Annual Meeting

May 12, 2020

MacroGenics Provides Update on Corporate Progress and First Quarter 2020 Financial Results

May 4, 2020

MacroGenics Announces Presentations at the 2020 ASCO Annual Meeting

April 28, 2020

MacroGenics to Host its Annual Meeting of Stockholders in Virtual Format

April 27, 2020

MacroGenics Announces Date of First Quarter 2020 Financial Results Conference Call

April 27, 2020

MacroGenics Announces Presentation of Flotetuzumab Translational Data at the 2020 AACR Annual Meeting

April 26, 2020

MacroGenics Announces Departure of Chief Medical Officer

March 3, 2020

MacroGenics Provides Update on Corporate Progress and 2019 Financial Results

February 24, 2020

MacroGenics Announces Date of Fourth Quarter and Full Year 2019 Financial Results Conference Call

February 12, 2020

MacroGenics Announces Submission of Margetuximab Biologics License Application to U.S. FDA

December 18, 2019

MacroGenics Presents Results from the SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer at the San Antonio Breast Cancer Symposium

December 10, 2019

MacroGenics Provides Update on Corporate Progress and Third Quarter 2019 Financial Results

November 5, 2019

MacroGenics Announces Flotetuzumab Presentations at the ASH Annual Meeting 2019

November 5, 2019

MacroGenics Announces Date of Third Quarter 2019 Financial Results Conference Call

October 29, 2019

MacroGenics Announces Initiation of Phase 2/3 MAHOGANY Study of Margetuximab in Gastric or Gastroesophageal Junction Cancer

October 24, 2019

MacroGenics Announces Second Interim Overall Survival Data from Phase 3 SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer

October 21, 2019

← Newer news releases

Calls

The 5 newest of 16 calls. Every call is listed under its year.

Decks

The 5 newest of 8 decks. Every deck is listed under its year.